Leo Pharma acquires worldwide rights to dersimelagon for up to $435M
Danish drugmaker LEO Pharma agreed to acquire the worldwide rights to dersimelagon from Tanabe Pharma for up to $435 million in upfront and milestone payments on August 18, 2026. Dersimelagon is an experimental oral treatment for rare genetic skin disorders erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The acquisition supports LEO Pharma's expansion into rare diseases as it prepares for a potential initial public offering.
Dersimelagon acquisition deal terms
▪Danish drugmaker LEO Pharma agreed to acquire the worldwide rights to the drug candidate dersimelagon from Tanabe Pharma for up to $435 million in upfront and near-term milestone payments on August 18, 2026.
▪The acquisition agreement for dersimelagon includes potential downstream milestone payments and tiered royalties on net sales for Tanabe Pharma.
LEO Pharma rare disease expansion
▪LEO Pharma previously partnered with Boehringer Ingelheim on the drug Spevigo in July 2025 and agreed to acquire U.S. drug developer Replay in April 2026.
▪The acquisition of dersimelagon is part of LEO Pharma's strategy to expand its portfolio into treatments for rare genetic skin diseases.
▪LEO Pharma is pursuing acquisitions and partnerships to build future growth drivers as the company positions itself for a potential initial public offering.
Dersimelagon EPP treatment profile
▪LEO Pharma CEO Christophe Bourdon stated that erythropoietic protoporphyria (EPP) is a significant unmet need affecting potentially 5,000 patients in the United States.
▪Dersimelagon is an experimental oral treatment for erythropoietic protoporphyria (EPP), a rare genetic disorder that causes extreme sensitivity to sunlight.
▪The U.S. Food and Drug Administration could approve dersimelagon as early as 2027, with LEO Pharma planning no delay between approval and commercial launch.
▪Dersimelagon works by increasing melanin in the body to help protect patients against painful light-induced reactions.
Dersimelagon XLP treatment profile
▪Dersimelagon is an experimental oral treatment for erythropoietic protoporphyria (EPP), a rare genetic disorder that causes extreme sensitivity to sunlight.
▪If approved by regulators, dersimelagon would become the first oral treatment available for both erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
Story comments
Loading comments…